Spyre Therapeutics, Inc. Common Stock
SYRE
$94.93
-3.46%
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. It is a niche player in the biotech space, focusing on extended half-life antibodies targeting α4β7, TL1A, and IL-23 as monotherapies and pair-wise combinations. The current investor narrative centers on the company's promising pipeline and recent clinical progress, which have driven a massive stock surge, but concerns about dilution from a proposed public offering and the lack of approved products keep the stock in a high-risk, high-reward debate.…
SYRE
Spyre Therapeutics, Inc. Common Stock
$94.93
Related headlines
SYRE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Spyre Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $105.79 and implied upside of +11.4% versus the current price.
Average Target
$105.79
0 analysts
Implied Upside
+11.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$88 - $135
Analyst target range
Spyre is covered by 15 analysts, with a consensus recommendation of 'Strong Buy' (mean recommendation of 1.0 on a 1-5 scale). The average target price is $103.93, implying a modest +1.8% upside from the current price of $102.13. The distribution shows no hold or sell ratings, indicating unanimous bullish sentiment among analysts. The target range spans from $78.00 (low) to $135.00 (high). The high target of $135.00 assumes successful pipeline development and potential regulatory approvals, while the low target of $78.00 reflects risks such as clinical trial failures or dilution from capital raises. The wide spread between low and high (57.7% difference) signals high uncertainty about the stock's future. Recent ratings from firms like Mizuho, Deutsche Bank, and BTIG have all been positive, with no downgrades, reinforcing the bullish consensus. However, the modest upside to the average target suggests that much of the optimism is already priced in.
Drowning in data?
Find the real signal!
Bulls vs Bears: SYRE Investment Factors
Spyre Therapeutics presents a high-risk, high-reward profile typical of clinical-stage biotech. The bull case is supported by unanimous analyst bullishness, a strong balance sheet with no debt, and a pipeline that has driven a 480% stock surge over the past year. However, the bear case is equally compelling: the company has no recurring revenue, deep operating losses, an extreme valuation premium (PB 15.85 vs. industry 4-6x), and imminent dilution from a public offering. The most critical tension is whether the pipeline's clinical success will materialize into approved products and revenue before the cash burn forces further dilutive financing. Currently, the evidence slightly favors the bulls given the strong analyst consensus and momentum, but the risk of a pullback is significant.
Bullish
- Unanimous Strong Buy Consensus: All 15 analysts rate SYRE a Strong Buy with a mean recommendation of 1.0, and the average target price of $103.93 is only 1.8% above the current price, indicating that the stock is fairly valued but with strong institutional conviction.
- Massive Upside from Pipeline Progress: The stock has surged 480.3% over the past year, dramatically outperforming the S&P 500's 16.5% gain, driven by positive clinical data for its long-acting antibody pipeline targeting IBD and rheumatic diseases.
- Strong Balance Sheet with No Debt: Spyre has zero debt (debt-to-equity ratio of 0) and a current ratio of 13.3, indicating ample liquidity to fund operations despite a cash burn of $57.5 million in Q1 2026.
- High Analyst Target Potential: The analyst high target of $135.00 implies a 32.2% upside from the current price of $102.13, reflecting optimism about pipeline success and potential regulatory approvals.
Bearish
- Pre-Revenue with Deep Losses: Spyre reported $0 revenue in Q1 2026 and a net loss of $69.0 million, with trailing twelve-month free cash flow of -$185.8 million, highlighting the high cash burn and lack of product sales.
- Extreme Valuation Premium: The price-to-book ratio of 15.85 is 3-4x the biotechnology industry average of 4-6x, and near the upper end of its historical range (0.49 to 26.02), suggesting the market is pricing in optimistic expectations.
- Dilution Risk from Public Offering: Spyre announced a proposed public offering in April 2026, and the company raised $312.9 million from stock issuance in Q4 2025, which will dilute existing shareholders and pressure the stock price.
- High Volatility and Beta: With a beta of 3.024, the stock is three times more volatile than the market, amplifying downside risk in any market downturn, and the short ratio of 7.57 indicates elevated short interest.
SYRE Technical Analysis
The stock is in a powerful sustained uptrend, with a 1-year price change of +480.3%, dramatically outperforming the S&P 500's +16.5%. Currently trading at $102.13, it sits at 97.2% of its 52-week range (low $14.51, high $105.09), indicating strong momentum near the top of the range. This positioning suggests bullish sentiment but also potential overextension, as the stock has rallied sharply from its lows. Short-term momentum remains robust, with a 1-month change of +18.4% and a 3-month change of +46.6%, both significantly outpacing the S&P 500's respective gains of 0.8% and 3.5%. The 1-month trend aligns with the longer-term uptrend, showing no divergence, and the relative strength index (RSI) is not provided, but the consistent upward price action implies strong buying pressure. The stock's beta of 3.024 indicates it is roughly three times more volatile than the market, amplifying both upside and downside risks. Key support lies at the 52-week low of $14.51, while resistance is at the 52-week high of $105.09. A breakout above $105.09 would signal continued momentum, while a breakdown below recent support near $90 could indicate a pullback. The high beta suggests that any market downturn could lead to sharp declines, making position sizing critical.
Beta
3.03
3.03x market volatility
Max Drawdown
-16.8%
Largest decline past year
52-Week Range
$15-$105
Price range past year
Annual Return
+483.8%
Cumulative gain past year
| Period | SYRE Return | S&P 500 |
|---|---|---|
| 1m | +9.6% | +1.7% |
| 3m | +33.7% | +4.7% |
| 6m | +196.0% | +10.4% |
| 1y | +483.8% | +21.9% |
| ytd | +210.4% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYRE Fundamental Analysis
Spyre is a pre-revenue biotech, with Q1 2026 revenue of $0 and a net loss of $69.0 million, compared to Q4 2025 revenue of $90.5 million (which included a one-time licensing or milestone payment). The company's revenue trajectory is inconsistent, with most quarters showing zero revenue, and the Q4 2025 spike appears non-recurring. The lack of recurring revenue underscores the early-stage nature of the business, and the investment case hinges entirely on pipeline success. The company is deeply unprofitable, with a net loss of $69.0 million in Q1 2026 and a trailing twelve-month free cash flow of -$185.8 million. Gross margin is 0% in most quarters, as there are no product sales. Operating expenses, primarily R&D ($60.4 million in Q1 2026) and SG&A ($15.2 million), are driving the losses. The net loss has widened from -$11.2 million in Q3 2025 to -$69.0 million in Q1 2026, indicating escalating spending as the pipeline advances. Spyre has no debt (debt-to-equity ratio of 0) and a current ratio of 13.3, suggesting ample liquidity. However, it is burning cash rapidly, with operating cash flow of -$57.5 million in Q1 2026. The company raised $312.9 million from stock issuance in Q4 2025, and a proposed public offering in April 2026 indicates further dilution. ROE is -21.7%, reflecting negative shareholder equity returns. The company is dependent on external financing to fund operations, as free cash flow is deeply negative.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-185801000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYRE Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric, but with zero revenue in most quarters, the PS ratio is undefined. Therefore, we use the price-to-book (PB) ratio, which is 15.85, as the most relevant metric. The trailing PE is -16.55 and forward PE is -32.65, both negative due to losses, so they are not meaningful. The PB ratio of 15.85 is extremely high, reflecting the market's valuation of the company's assets and pipeline potential. Compared to the biotechnology industry average PB ratio (typically around 4-6x), Spyre trades at a significant premium of roughly 3-4x the industry. This premium is justified by the company's promising pipeline and recent clinical data, but it also implies high expectations for future success. Historically, Spyre's PB ratio has ranged from 0.49 (June 2022) to 26.02 (March 2026). The current PB of 15.85 is near the upper end of its historical range, suggesting the market is pricing in optimistic expectations. This could indicate that the stock is overvalued relative to its own history, but it also reflects the positive sentiment around its pipeline milestones.
PE
-16.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-53.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Spyre's primary financial risk is its pre-revenue status and heavy cash burn. In Q1 2026, the company reported $0 revenue and a net loss of $69.0 million, with operating cash flow of -$57.5 million. The trailing twelve-month free cash flow is -$185.8 million, and while the company has no debt and a current ratio of 13.3, it will need to raise additional capital to fund operations. The proposed public offering in April 2026 will dilute existing shareholders, and the net loss has widened from -$11.2 million in Q3 2025 to -$69.0 million in Q1 2026, indicating escalating R&D spending. The negative ROE of -21.7% and negative profit margins underscore the lack of profitability.
Market & Competitive Risks: The stock's beta of 3.024 makes it highly sensitive to market downturns, and its extreme valuation premium (PB 15.85 vs. industry average 4-6x) exposes it to multiple compression if sentiment shifts. The biotechnology sector is competitive, with many companies targeting IBD and rheumatic diseases, and any clinical trial failure could lead to a sharp re-rating. The short ratio of 7.57 suggests significant bearish positioning, and the stock's 480% gain over the past year may attract profit-taking. Recent news of a proposed public offering adds uncertainty, and the wide analyst target range ($78-$135) reflects high uncertainty.
Worst-Case Scenario: In a worst-case scenario, a clinical trial failure or regulatory setback could cause the stock to collapse to its 52-week low of $14.51, representing a -85.8% decline from the current price of $102.13. Additionally, if the company fails to secure further financing, it may face bankruptcy or forced asset sales. The historical max drawdown of -16.79% is modest, but given the stock's volatility, a drawdown of 50% or more is plausible in a severe adverse event.